Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Hospital Charity Care
  • Single-Payer Healthcare
  • TrumpRx
  • Pharmacy Discount Coupons
  • Decoding Health Insurance Terms

WHAT'S NEW

  • Hospital Charity Care
  • Single-Payer Healthcare
  • TrumpRx
  • Pharmacy Discount Coupons
  • Decoding Health Insurance Terms

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Mar 30 2026

Full Issue

Viewpoints: There Are Pitfalls To Using AI In Therapy; Congress, Regulators Have A Practical Plan To Rein In PBMs

Opinion writers discuss these public health issues.

The New York Times: Your Chatbot Isn’t A Therapist

As clinicians at a major academic medical center, we have seen our patients turn to chatbots powered by large language models for emotional support that they would once have sought from family or friends — to discuss their fears, loneliness and uncertainty. This troubles us. (Divya Saini and Natasha Bailen, 3/29)

Stat: To Lower Drug Prices, Give PBMs A Fiduciary Duty To Patients 

Consumer groups, independent pharmacies, and drugmakers rightly complained for years that pharmacy benefit managers (PBMs) have used their position as supply chain middlemen to benefit themselves at the expense of patients and payers. At last, relief is in sight. Congress and the Department of Labor are now poised to align PBMs’ incentives with employers and patients, including making PBMs legally accountable as fiduciaries. (Neeraj Sood, 3/30)

Capital & Main: The Least-Bad Option: A County Sales Tax To Save California Health Clinics

The idea of increasing the sales tax doesn’t thrill anyone. As Los Angeles County Supervisor Holly Mitchell said after the board approved putting the measure on the June ballot, “There really are no other viable and timely options. Trust me, I looked high and low.” The immediate alternative, though, is reduced or suspended operations at clinics and health centers at a time when they are likely to be desperately needed by the county’s poorest, a growing group that includes documented and undocumented immigrants alike, as well as U.S. citizens. (Mark Kreidler, 3/26)

The CT Mirror: Long Covid Vs UConn’s GA Health Insurance

I wake up in the morning and assess my symptoms. For me, it is usually some cocktail of brain fog, fatigue, muscle pain and/or restless legs, pins and needles in my toes, and post exertional malaise. After the disappointment that I still woke up chronically ill, I check my sleep score on my fitbit and do either brain training or a meditation through an app that’s main purpose is to help me believe that I can recover. (Kelly Schlabach, 3/27)

Stat: In Memory Of Former Global Health Pioneer Barry Bloom 

When Barry R. Bloom was diagnosed with pancreatic cancer, he decided to be a data point. He signed up for clinical trials, and, as was his way, he read all the papers and came to his appointments with questions and wanting to learn as much as he could. When he entered a Phase 1 study of a molecular inhibitor of his tumor’s KRAS mutation and saw a tremendous response, he knew it was temporary. A single inhibiting agent was bound to select for resistance — he knew it was a matter of time. (Marc Lipsitch and Yonatan Grad, 3/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF